Assuming therapeutics is required, the following 20 results were found.
-
recrudescent, or recurring, disease in survivors—especially those treated with standard-of-care monoclonal antibody therapeutics—were largely unknown. So Zeng and his team at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
Spero Therapeutics, Inc. today announced that it was awarded funding of $15.7 million, with the potential for up to an additional $28.5 million over 5 years, from the Biomedical Advanced Research and Development Authority (BARDA). The funding will...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
on Twitter Share on LinkedIn Email this page Print this page Todd Aguilera, M.D., Ph.D., a member of the Experimental Therapeutics Program in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern, is a Damon Runyon Clinical Investigator...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
and JN.1 circulation (van Werkhoven, December 2023 - preprint, not peer-reviewed; Hansen, January 2024). Q: Do other therapeutics protect against JN.1? A: Yes. Despite accumulated mutations by JN.1, therapeutics, such as Paxlovid, are still expected to...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
C-T-D-Squared). CTD2 was created to bridge the gap between genomics (the study of all the DNA in a cell) and cancer therapeutics. It’s an outgrowth of the NCI and the National Human Genome Research Institute’s The Cancer Genome Atlas, which has helped...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
to large affected areas or open wounds. This need has led researchers from DTRA to pursue new personnel decontamination therapeutics. Recent USAMRICD studies have shown that the median lethal dose of VX in Veriox®-treated animals is 1.8-fold higher than...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
threats and investigates disease outbreaks and threats to public health. Research conducted at USAMRIID leads to therapeutics, vaccines, diagnostics, and information that benefit both military personnel and civilians. USAMRIID is currently providing...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
John M. Dye, Jr., Ph.D., is a viral immunologist with USAMRIID. His work has focused on filovirus vaccines and therapeutics, with years of intense research to combat Ebola and related viruses. “Our specific goal is to develop medical countermeasures,...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
enzyme inhibited by nerve agents, has contributed immeasurably to the efforts to develop bioscavenger prophylaxis and therapeutics against chemical warfare nerve agents. The title of Sussman’s award lecture was “Acetylcholinesterase – From 3D Structure...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
threats and investigate disease outbreaks and threats to public health. Research conducted at USAMRIID leads to therapeutics, vaccines, diagnostics, and information that benefit military personnel and civilians. USAMRICD is the nation’s leading science...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
in RT-PCR can be used as a (time-dependent) proxy indicator of JN.1 (versus other Omicron lineages) infection. Therapeutics: Last Updated March 1, 2024 Paxlovid continues to be effective against emerging SARS-CoV-2 variants, including JN.1. Content...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.
VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.